| Active, not recruiting | 2 | 40 | US | Lenalidomide and bb2121, ide-cel, revlimid | Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS | Multiple Myeloma | 01/25 | 04/25 | | |
NCT05191472: Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies |
|
|
| Terminated | 2 | 3 | US | Pembrolizumab, Keytruda, Lambrolizumab, MK-3475 | Alfred Chung, MD, Merck Sharp & Dohme LLC | Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | 12/23 | 12/23 | | |
